BRAF and thyroid gland papillary carcinoma: Approximately 40-60% of papillary carcinomas exhibit the BRAF V600E mutation, which leads to constitutive activation of the mitogen-activated protein kinase (MAPK) signaling pathway, thereby promoting cell proliferation and survival (59).